Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aileron Therapeutics (Nasdaq: ALRN) has announced a pre-recorded corporate presentation scheduled for September 12, 2022, at 7:00 a.m. ET, during the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will focus on the company's chemoprotection oncology efforts to enhance chemotherapy safety and effectiveness. It will be accessible on-demand through the company's website and archived for 30 days. Aileron's lead product, ALRN-6924, targets p53-mutated cancers, aiming to improve patients' quality of life and treatment tolerability.
- None.
- None.
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that a pre-recorded corporate presentation by Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will become available for on-demand viewing at the H.C. Wainwright 24th Annual Global Investment Conference, on Monday, September 12, 2022, at 7:00 a.m. ET.
The presentation will be available under the Investors & Media section of the company's website at aileronrx.com. A replay of the webcast will be archived on the Aileron website for approximately 30 days following the presentation.
About Aileron Therapeutics
Aileron is a clinical stage chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which we exclusively focus on treating patients with p53-mutated cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients’ quality of life and help them better tolerate chemotherapy. Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy. Our vision is to bring chemoprotection to all patients with p53-mutated cancers, which represent approximately
| Investor Contact: | Media Contact: |
| Stern Investor Relations | Liz Melone |
| Alexander Lobo | 617-256-6622 |
| alex.lobo@sternir.com | lmelone@aileronrx.com |
FAQ
What is the date of the Aileron Therapeutics presentation at the H.C. Wainwright conference?
What product is being highlighted by Aileron Therapeutics during the conference?
Where can I view the Aileron Therapeutics conference presentation?
How long will the Aileron Therapeutics presentation be available for viewing?
What is the focus of Aileron Therapeutics' research?
